When CIN 2 and CIN 3 can be differentiated, these designations can be reported along with the HSIL diagnosis. However, after thoughtful deliberation, the delegates to the ASCCP consensus conference decided that there is not yet enough outcome data available to determine different management strategies when using the new LAST histopathology terminology. They recommended that, until evidence is available, results reported as histologic (not cytologic) LSIL should be managed as CIN 1, and histologic (not cytologic) HSIL should be managed as CIN 2/CIN 3.
WHAT THIS EVIDENCE MEANS FOR PRACTICE
Guidelines for the management of abnormal cervical cytology, CIN, and AIS are necessarily complicated, but they provide the best basis for evidence-based management of these medical challenges. The Web provides easy access to all of the ASCCP guidelines via www.asccp.org, www.jlgtd.com, and www.greenjournal.org.
We want to hear from you! Tell us what you think.